Australia TGA explains transition provisions for human tissue-based products
This article was originally published in Clinica
Executive Summary
Sponsors of human cellular and tissue-based therapies currently on the market in Australia who apply for formal product registration by 30 November this year will get a guarantee that their products will remain on the market after May 2014 – when new rules on the licensing of biologicals become mandatory – if an official assessment of the product has not been completed by then.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.